PepGen Ltd Asset Resilience Ratio
PepGen Ltd asset resilience ratio. PepGen Ltd (PEPG) has an Asset Resilience Ratio of 66.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of PepGen Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PepGen Ltd (2022–2025)
Asset resilience ratio of PepGen Ltd from 2022 to 2025. This chart shows how PepGen Ltd's Asset Resilience Ratio has changed over time. Read PEPG total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PepGen Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PepGen Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $94.47 Million | 66.81% |
| Total Liquid Assets | $94.47 Million | 66.81% |
Asset Resilience Insights
- Very High Liquidity: PepGen Ltd maintains exceptional liquid asset reserves at 66.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PepGen Ltd Industry Peers by Asset Resilience Ratio
Compare PepGen Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
PepGen Ltd Asset Resilience Ratio by Year (2022–2025)
PepGen Ltd asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for PepGen Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.57% | $87.94 Million | $173.91 Million | +3.66pp |
| 2024-12-31 | 46.90% | $70.77 Million | $150.88 Million | +26.19pp |
| 2023-12-31 | 20.71% | $29.63 Million | $143.05 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $217.44 Million | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more